Pediatric inflammatory bowel disease in New Zealand study: a 10-year update on national incidence and point…

Abstract

Background and Aims: The incidence of inflammatory bowel disease (IBD) in children is increasing worldwide, with high rates previously noted in New Zealand. The incidence and prevalence of pediatric IBD in New Zealand was last delineated in 2015. The aim of this study was to provide updated epidemiological data by delineating the incidence and prevalence of pediatric IBD in New Zealand ten years after the previous assessment.

Methods: For the incidence cohort, patients younger than 16 years with IBD, diagnosed between January 1, 2025 and December 31, 2025 were identified and information entered into a secure database. Population data were obtained and incidence calculated. To derive the point prevalence, all patients diagnosed with IBD under the age of 16 years on June 30, 2025 were identified and information entered into a secure database. Population data were obtained and prevalence calculated.

Results: The incidence of pediatric IBD, Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease-unclassified (IBD-U) in New Zealand in 2025 was 8.0, 5.6, 2.0, and 0.4 per 100 000 respectively. The point prevalence of IBD, CD, UC, and IBD-U in children in New Zealand on June 30, 2025 was 33.0, 21.7, 8.1, and 3.2 per 100 000 respectively.

Conclusions: The incidence and prevalence of IBD have increased 1.5 times in children in New Zealand since 2015. New Zealand continues to have some of the highest rates of pediatric IBD in the world. Ongoing research is needed to understand factors leading to increasing rates and to ensure appropriate health service provision.

Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study
Nabeel Khan, Ramaswamy Sundararajan, Freddy Caldera +1
Inflammatory Bowel Diseases23 Jun 2026Peer-reviewedCC BY 4.0Full textEpidemiology & public healthPMC
National trends in chronic kidney disease prevalence by sleep duration in South Korea, 2007 to 2022 : A nationwide cross-sectional study
Jeongseon Oh, Yesol Yim, Hyeon Jin Kim +10
Medicine9 Oct 2026Peer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance
Tina H. Tran, Daniel Park, Regina‐Celeste Ahmad +3
JPGN reports12 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Incidence, Prevalence, Mortality, and Disability‐Adjusted Life Years Due to Cancer Among Adolescents Aged 10–19 Years in Iran, 1990–2023: A Trend Analysis of the Global Burden of Disease Study
Habibollah Azarbakhsh, Andishe Hamedi, Sanaz Amiri +3
Health science reports1 Nov 2026Peer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
Incidence and Outcomes of Human Adenovirus Infection and Disease in a Multicenter Cohort of Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
Brian T Fisher, Jesse A Blumenstock, Craig L K Boge +17
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America20 Aug 2026Peer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthPMC

Cite

BibTeX RIS

BibTeX

@article{cherry2026pediatric,
  title = {{Pediatric inflammatory bowel disease in New Zealand study: a 10-year update on national incidence and point prevalence in 2025}},
  author = {Canada T L Cherry and Helen M Evans and Stephen W Mouat and Jonathan R Bishop and Amin J Roberts and Nir Fireman and Ashwin Bhana and Jillian J Haszard and Andrew S Day and Robert N Lopez},
  journal = {Crohn's \& colitis 360},
  year = {2026},
  month = oct,
  doi = {10.1093/crocol/otag117},
  url = {https://europepmc.org/article/PMC/PMC13728852},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Pediatric inflammatory bowel disease in New Zealand study: a 10-year update on national incidence and point prevalence in 2025
AU  - Canada T L Cherry
AU  - Helen M Evans
AU  - Stephen W Mouat
AU  - Jonathan R Bishop
AU  - Amin J Roberts
AU  - Nir Fireman
AU  - Ashwin Bhana
AU  - Jillian J Haszard
AU  - Andrew S Day
AU  - Robert N Lopez
PY  - 2026
DA  - 2026/10/01
JO  - Crohn's & colitis 360
DO  - 10.1093/crocol/otag117
UR  - https://europepmc.org/article/PMC/PMC13728852
AB  - Background and Aims: The incidence of inflammatory bowel disease (IBD) in children is increasing worldwide, with high rates previously noted in New Zealand. The incidence and prevalence of pediatric IBD in New Zealand was last delineated in 2015. The aim of this study was to provide updated epidemiological data by delineating the incidence and prevalence of pediatric IBD in New Zealand ten years after the previous assessment.  Methods: For the incidence cohort, patients younger than 16 years with IBD, diagnosed between January 1, 2025 and December 31, 2025 were identified and information entered into a secure database. Population data were obtained and incidence calculated. To derive the point prevalence, all patients diagnosed with IBD under the age of 16 years on June 30, 2025 were identified and information entered into a secure database. Population data were obtained and prevalence calculated.  Results: The incidence of pediatric IBD, Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease-unclassified (IBD-U) in New Zealand in 2025 was 8.0, 5.6, 2.0, and 0.4 per 100 000 respectively. The point prevalence of IBD, CD, UC, and IBD-U in children in New Zealand on June 30, 2025 was 33.0, 21.7, 8.1, and 3.2 per 100 000 respectively.  Conclusions: The incidence and prevalence of IBD have increased 1.5 times in children in New Zealand since 2015. New Zealand continues to have some of the highest rates of pediatric IBD in the world. Ongoing research is needed to understand factors leading to increasing rates and to ensure appropriate health service provision.
SN  - 2631-827X
ER  -

Abstract

Related

Cite